Whitehawk Therapeutics (WHWK) Common Equity (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Common Equity data on file, last reported at $116.2 million in Q1 2026.

• On a quarterly basis, Common Equity fell 47.6% year-over-year to $116.2 million in Q1 2026; TTM through Mar 2026 was $116.2 million, a 47.6% decrease from a year earlier, with the FY2025 full-year figure at $136.3 million, up 159.75% from the prior year.
• Common Equity for Q1 2026 stood at $116.2 million, down from $136.3 million in the prior quarter.
• Over the last five years, Common Equity for WHWK reached as high as $221.7 million in Q1 2025 and fell as low as $52.5 million in Q4 2024.
• Historically, Common Equity has averaged $126.8 million across 5 years, with a median of $124.6 million in 2022.
• Across the five-year window, Common Equity soared 797.34% in 2022 and slumped 50.11% in 2024, its largest moves.
• Year by year, Common Equity stood at $158.4 million in 2022, then sank by 33.58% to $105.2 million in 2023, then slumped by 50.11% to $52.5 million in 2024, then soared by 159.75% to $136.3 million in 2025, then decreased by 14.77% to $116.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $116.2 million in Q1 2026, $136.3 million in Q4 2025, and $157.2 million in Q3 2025.